3Billion Inc is a Korea-based company principally engaged in the provision of genetic testing services. The Company is principally engaged in the provision of rare genetic disease diagnostic testing services. The Company is also engaged in the research and development of technology that automatically reads the pathogenicity of numerous genetic variants found in the genome.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
07/08/26	KRW 6,080.00	-3.18%	53,586
06/08/26	KRW 6,280.00	+1.62%	142,628
05/08/26	KRW 6,180.00	+3.52%	136,245
04/08/26	KRW 5,970.00	+14.37%	249,462
03/08/26	KRW 5,220.00	+1.56%	91,050

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. Other stock markets 07/08/2026			5-day change	1st Jan Change
6,080.00 ^KRW	-3.18%		+18.29%	-66.65%

01/06	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
13/05	3billion, Inc. announced that it has received KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI

Market Cap	193B 137M 119M 111M 102M 191M 13.06B 194M 1.3B 511M 6.55B 515M 504M 21.65B	P/E 2025	-107x	P/E 2026 *	-
Enterprise Value	177M 125K 108K 101K 92.84K 175K 11.92M 177K 1.19M 466K 5.98M 470K 460K 19.76M	EV / Sales 2025	49x	EV / Sales 2026 *	-
Free-Float	75.48%	Yield 2025 *	-	Yield 2026 *	-

01/06	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
13/05	3billion, Inc. announced that it has received KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI
23/04	3billion, Inc. announced that it expects to receive KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd. and other investors.	CI
09/04	3Billion Inc wins 955 million won order	RE
23/03	3billion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
18/03/25	3Billion Inc Wins 655 Million Won Order	RE

1 day	-3.18%
1 week	+18.29%
Current month	+18.29%
1 month	+4.47%
3 months	-48.34%
6 months	-53.90%
Current year	-66.65%

3billion, Inc. Stock

Stocks

A394800

KR7394800007

Biotechnology & Medical Research

Valuation: 3billion, Inc.

Chart: 3billion, Inc.

Latest news : 3billion, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: 3billion, Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	4,920	6,560
1 month	4,260	6,560
Current year	4,260	18,690
1 year	4,260	20,100
3 years	3,025	20,100
5 years	3,025	20,100
10 years	3,025	20,100

Manager	Title	Age	Since
Chang-Won Geum CEO	Chief Executive Officer	45	10/10/2016
Soon-Il Park DFI	Director of Finance/CFO	46	01/10/2020
Jeong-Seol Lee CTO	Chief Tech/Sci/R&D Officer	46	01/08/2018

Director	Title	Age	Since
Chang-Won Geum BRD	Director/Board Member	45	10/10/2016
Se-Hwan Kim BRD	Director/Board Member	44	10/10/2016
Ki-Hyeon Kang BRD	Director/Board Member	44	18/11/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/4/25	Soon-Il Park	Others	Chief Financial Officer	44,000	0.1387%
7/3/25	Soon-Il Park	Fiscal year	Chief Financial Officer	40,000	0.1262%
7/3/25	Ki-hyun Kang	Fiscal year		10,000	0.0316%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
3BILLION, INC.	-3.18%	+18.29%	-4.25%	-	137M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+5.64%	+10.46%	+98.80%	+272.09%	3.98B
VERACYTE, INC.	+2.32%	+1.94%	+70.59%	+90.48%	3.8B
IOVANCE BIOTHERAPEUTICS, INC.	+2.09%	+55.77%	+140.15%	-10.07%	2.87B
CAREDX, INC.	+4.20%	+6.82%	+286.83%	+332.31%	2.42B
BGI GENOMICS CO., LTD.	+4.99%	+4.72%	-25.28%	-32.77%	2.27B
FREENOME, INC.	+2.20%	0.00%	+5.49%	-	1.26B
SEEGENE, INC.	+0.70%	+7.43%	-3.67%	+25.65%	934M
MARAVAI LIFESCIENCES HOLDINGS, INC.	-0.32%	-5.18%	+207.65%	-43.47%	919M
HANGZHOU ALLTEST BIOTECH CO., LTD.	+3.09%	+3.92%	-37.86%	-5.07%	532M
Average	+2.17%	+10.34%	+73.85%	+78.64%	1.91B
Weighted average by Cap.	+3.30%	+12.84%	+97.96%	+118.89%

	2025	2026 *
Net sales	10.8B 7.66M 6.63M 6.19M 5.68M 10.68M 729M 10.85M 72.62M 28.5M 366M 28.77M 28.14M 1.21B	-
Net income	-5.8B -4.12M -3.56M -3.32M -3.05M -5.74M -392M -5.83M -39M -15.31M -196M -15.45M -15.11M -649M	-
Net Debt	-16.9B -11.99M -10.37M -9.69M -8.89M -16.71M -1.14B -16.98M -114M -44.6M -572M -45.03M -44.04M -1.89B	-